BioMarin Reports Positive Phase 3 VOXZOGO Data for Hypochondroplasia in NEJM Evidence

BioMarin Pharmaceutical announced positive Phase 3 study results for VOXZOGO (vosoritide) in children with hypochondroplasia, published in NEJM Evidence. The drug demonstrated significant improvements across multiple growth measures and maintained a consistent safety profile. This data supports BioMarin's recent supplemental New Drug Application to the FDA, aiming to expand VOXZOGO's treatment indication for this rare genetic condition.